article thumbnail

AmerisourceBergen agrees to acquire PharmaLex for $1.29bn

Pharmaceutical Technology

The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product. Additionally, it aids clients in introducing products to international markets and varied patient populations by delivering tech-driven services spanning from clinical development consultation to marketing authorisation.

article thumbnail

GSK requires supplier sustainability compliance from 2023

European Pharmaceutical Review

Moreover, pharmaceutical manufacturing poses a huge detriment to the state of the planet’s ecosystem. Active pharmaceutical ingredients (APIs) are particularly impact intensive, soaking up a large quantity of resources in terms of heat, energy and water when being produced.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

In particular, for the pharmaceutical industry, these talent shortages bring about a host of difficult challenges. This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Training and development.

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Impending change affords an opportunity for innovation.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Green Chemistry in the Synthesis of Pharmaceuticals.